+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
AI Pharma Market - Global Forecast 2026-2032- Product Image
AI Pharma Market - Global Forecast 2026-2032- Product Image
Sale

AI Pharma Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6153333
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The AI Pharma Market is projected to reach USD 2.57 Billion in 2026. It is expected to continue growing at a CAGR of 14.47%, reaching USD 5.80 Billion by 2032.

AI Pharma: Executive Overview

Artificial intelligence is reshaping pharmaceutical research, development, manufacturing, and commercialization by improving how organizations process scientific, clinical, operational, and real-world data. Its use spans target identification, molecule design, clinical-trial planning, pharmacovigilance, regulatory documentation, supply-chain management, and personalized treatment support. Adoption remains closely linked to data quality, validation, cybersecurity, privacy, intellectual-property protection, and the ability to demonstrate reliable outcomes in regulated settings.

Transformative Shifts Across Pharmaceutical Operations

Pharmaceutical organizations are moving from isolated analytics projects toward integrated AI capabilities embedded in research and enterprise workflows. Generative AI is accelerating document review, knowledge retrieval, protocol drafting, and scientific communication, while machine learning supports biomarker discovery, trial recruitment, image analysis, demand planning, and manufacturing control. This shift is also changing operating models: cross-functional teams increasingly combine domain scientists, clinicians, data specialists, quality professionals, legal experts, and technology leaders. The most durable transformation depends on governed data foundations, reproducible validation, human oversight, and clear accountability for decisions influenced by algorithms.

How Artificial Intelligence Compounds Value Across the Value Chain

AI can create cumulative benefits when connected across the pharmaceutical value chain rather than deployed as disconnected tools. Better data curation can improve discovery models; improved candidate prioritization can support more focused preclinical work; stronger trial analytics can help identify suitable participants and detect operational risks earlier; and integrated safety monitoring can strengthen post-market learning. These benefits are not automatic. Bias in source data, inconsistent standards, limited explainability, model drift, and weak integration with laboratory, clinical, and manufacturing systems can reduce value or introduce risk. Accordingly, organizations are emphasizing model governance, validation records, audit trails, access controls, and continuous performance monitoring.

Regional Dynamics Shaping AI Pharma Adoption

North America is characterized by strong pharmaceutical, technology, research, and venture ecosystems, with adoption influenced by regulatory expectations, healthcare-data governance, and partnerships between industry, academia, and care providers. Europe places particular emphasis on privacy, ethical use, transparency, and harmonized regulatory practice, while national health systems create opportunities for evidence-based deployment. Asia-Pacific combines advanced pharmaceutical and technology capabilities with large and diverse patient populations; priorities include clinical development, manufacturing efficiency, translational research, and digital-health integration. Latin America is pursuing applications in access, clinical operations, diagnostics, and supply-chain visibility, although infrastructure and data-standardization gaps remain important considerations. The Middle East is investing in digital health, research capacity, and connected care, while the region’s AI Pharma agenda depends on workforce development, trusted data exchange, and regulatory maturity. Africa’s opportunities include disease surveillance, decentralized research support, supply-chain optimization, and broader access to expertise, with connectivity, funding, interoperability, and local data representation remaining central challenges.

Group-Level Priorities Across ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN members are navigating varied levels of digital infrastructure, regulatory development, and pharmaceutical capability, making interoperable standards and shared skills especially valuable. BRICS economies bring substantial scientific, manufacturing, and patient-data resources, while cooperation must address differing regulatory systems, data rules, and research priorities. The European Union is advancing a coordinated approach centered on trustworthy AI, privacy, medical-device and pharmaceutical compliance, and cross-border data governance. G7 members generally possess mature research and healthcare institutions, with priorities including secure innovation, resilient supply chains, responsible generative AI, and international standards. GCC countries are emphasizing health-system modernization, precision medicine, national data capabilities, and specialized talent. NATO members approach AI Pharma partly through resilience and security considerations, including protection of critical health infrastructure, cyber risk management, and continuity of pharmaceutical supply.

Country-Level Signals Across Major AI Pharma Markets

Australia is developing applications in clinical research, health-data analysis, and remote-care support, with privacy, Indigenous data governance, and evidence requirements shaping implementation. Brazil is applying AI to research, health-system operations, diagnostics, and supply chains while managing regional inequality and data-quality variation. Canada emphasizes research collaboration, health-data stewardship, and responsible innovation. China is advancing AI-enabled discovery, manufacturing, and clinical applications alongside strong attention to domestic data governance and regulatory oversight. France and Germany are strengthening digital-health, research, and industrial capabilities within European rules, with Germany also emphasizing manufacturing and health-system integration. India is using AI to support drug discovery, trial operations, affordable care, and pharmaceutical manufacturing, while addressing fragmented data and workforce needs. Italy and Spain are pursuing hospital, research, and production applications through national and European initiatives. Japan combines advanced life-science, robotics, and healthcare capabilities with an aging-population focus. Mexico is exploring applications in clinical services, manufacturing, and access, subject to infrastructure and specialist-capacity constraints. Russia’s AI Pharma development is shaped by domestic research, production, and data-governance priorities. South Korea is integrating strong technology and biopharmaceutical capabilities in discovery, diagnostics, and manufacturing. The United Kingdom continues to connect AI research with life sciences, clinical research, and health-system transformation. The United States remains a major center for AI-enabled pharmaceutical research, clinical development, healthcare analytics, and regulatory innovation, with privacy, safety, and accountability remaining key considerations.

Practical Priorities for Pharmaceutical Industry Leaders

Leaders should begin with clearly defined use cases tied to measurable scientific, clinical, quality, or operational outcomes rather than adopting AI solely for experimentation. Establish a governed data architecture with consistent metadata, provenance, access controls, and quality checks. Use risk-based validation and maintain human review for safety-critical or clinically consequential decisions. Create multidisciplinary AI governance that includes research, medical, regulatory, quality, cybersecurity, privacy, legal, and patient perspectives. Require transparent documentation of training data, model limitations, performance, monitoring, and change control. Invest in workforce development so scientists and operators can evaluate AI outputs critically. Finally, build partnership and procurement standards that address interoperability, intellectual property, security, auditability, and continuity of service.

Research Methodology for the AI Pharma Assessment

This executive summary is structured as a qualitative synthesis of established AI applications and implementation considerations across pharmaceutical research, development, manufacturing, safety, and healthcare operations. The assessment organizes insights by value-chain function, geography, economic and political group, and country, while emphasizing verifiable themes such as data governance, regulatory oversight, infrastructure, workforce capability, cybersecurity, and clinical validity. It intentionally excludes market estimates, market sizing, market shares, forecasts, and company-specific comparisons. Conclusions should be interpreted alongside current legislation, regulator guidance, peer-reviewed evidence, validated deployment results, and local health-data requirements.

Conclusion: Building Trusted, Scalable AI Pharma Capabilities

AI is becoming an important enabling layer across the pharmaceutical ecosystem, but durable impact will depend less on model novelty than on trustworthy data, rigorous validation, effective integration, and accountable leadership. Regional and national conditions will continue to shape priorities, from research acceleration and manufacturing resilience to equitable access and health-system modernization. Organizations that pair focused use cases with strong governance, interdisciplinary expertise, secure infrastructure, and continuous outcome evaluation will be better positioned to convert AI experimentation into reliable pharmaceutical value.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. AI Pharma Market, by Therapeutic Area
7.1. Introduction
7.2. Cardiovascular
7.3. Central Nervous System
7.4. Infectious Disease
7.5. Oncology
8. AI Pharma Market, by Technology
8.1. Introduction
8.2. Computer Vision
8.2.1. Image Recognition
8.2.2. Video Analytics
8.3. Deep Learning
8.3.1. Convolutional Neural Networks
8.3.2. Generative Adversarial Networks
8.3.3. Recurrent Neural Networks
8.4. Machine Learning
8.4.1. Reinforcement Learning
8.4.2. Supervised Learning
8.4.3. Unsupervised Learning
8.5. Nlp
8.5.1. Language Translation
8.5.2. Sentiment Analysis
8.5.3. Text Mining
8.6. Robotics
9. AI Pharma Market, by Product
9.1. Introduction
9.2. Hardware Solutions
9.3. Services
9.3.1. Clinical Trial Services
9.3.2. Drug Discovery Services
9.3.3. Patient Support Services
9.4. Software Solutions
9.4.1. Analytics Software
9.4.2. Platform Software
10. AI Pharma Market, by Business Model
10.1. Introduction
10.2. Consulting Services
10.2.1. Advisory
10.2.2. Implementation
10.3. Licensing Model
10.3.1. Perpetual License
10.3.2. Term License
10.4. Platform Model
10.5. Software As A Service
10.5.1. Pay Per Use
10.5.2. Subscription
11. AI Pharma Market, by Application
11.1. Introduction
11.2. Clinical Trials
11.2.1. Phase I
11.2.2. Phase II
11.2.3. Phase III
11.2.4. Phase IV
11.3. Diagnostic Tools
11.3.1. Biomarker Analysis
11.3.2. Imaging
11.4. Drug Discovery
11.4.1. Compound Screening
11.4.2. Preclinical Testing
11.4.3. Target Identification
11.5. Patient Monitoring
11.5.1. Remote Monitoring
11.5.2. Wearable Devices
11.6. Supply Chain Management
11.6.1. Cold Chain Logistics
11.6.2. Inventory Management
12. AI Pharma Market, by End User
12.1. Introduction
12.2. Contract Research Organizations
12.3. Hospitals
12.4. Patients
12.5. Pharmaceutical Companies
12.6. Research Institutes
13. AI Pharma Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. AI Pharma Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. AI Pharma Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. A2A Pharmaceuticals, Inc.
17.2. AbCellera Biologics Inc.
17.3. Adagene, Inc.
17.4. AiCure, Inc.
17.5. Aiforia Technologies Inc.
17.6. Aizon Network Corporation
17.7. Alector, Inc.
17.8. Altis Labs plc
17.9. Arpeggio Biosciences, Inc.
17.10. Arzeda, Inc.
17.11. Atomwise, Inc.
17.12. BenevolentAI Limited
17.13. Berg LLC
17.14. ChemPass Kft
17.15. Cloud Pharmaceuticals, Inc.
17.16. Cradle Bio B.V.
17.17. Exscientia plc
17.18. Insilico Medicine, Inc.
17.19. Isomorphic Labs Limited
17.20. Owkin, Inc.
17.21. Recursion Pharmaceuticals, Inc.
17.22. SOM Innovation Biotech, S.A.
17.23. XtalPi Holdings Limited
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global AI Pharma Market, Years Considered for the Study
FIGURE 2. Global AI Pharma Market, Research Design
FIGURE 3. Global AI Pharma Market, Research Framework
FIGURE 4. Global AI Pharma Market, Data Triangulation
FIGURE 5. Global AI Pharma Market Size, 2017-2032 (USD Million)
FIGURE 6. Global AI Pharma Market Size, by Therapeutic Area, 2025 vs 2032 (%)
FIGURE 7. Global AI Pharma Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global AI Pharma Market Size, by Technology, 2025 vs 2032 (%)
FIGURE 9. Global AI Pharma Market Size, by Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global AI Pharma Market Size, by Product, 2025 vs 2032 (%)
FIGURE 11. Global AI Pharma Market Size, by Product, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global AI Pharma Market Size, by Business Model, 2025 vs 2032 (%)
FIGURE 13. Global AI Pharma Market Size, by Business Model, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global AI Pharma Market Size, by Application, 2025 vs 2032 (%)
FIGURE 15. Global AI Pharma Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global AI Pharma Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global AI Pharma Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global AI Pharma Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global AI Pharma Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global AI Pharma Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global AI Pharma Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global AI Pharma Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global AI Pharma Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global AI Pharma Market Segmentation & Coverage
TABLE 2. Global AI Pharma Market Size, 2017-2032 (USD Million)
TABLE 3. Global AI Pharma Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 4. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Central Nervous System Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Central Nervous System Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Central Nervous System Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Infectious Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Infectious Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Infectious Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global AI Pharma Market Size, by Technology, 2017-2032 (USD Million)
TABLE 17. Global Computer Vision Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Computer Vision Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Computer Vision Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Image Recognition Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Image Recognition Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Image Recognition Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Video Analytics Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Video Analytics Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Video Analytics Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Deep Learning Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Deep Learning Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Deep Learning Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Convolutional Neural Networks Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Convolutional Neural Networks Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Convolutional Neural Networks Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Generative Adversarial Networks Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Generative Adversarial Networks Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Generative Adversarial Networks Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Recurrent Neural Networks Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Recurrent Neural Networks Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Recurrent Neural Networks Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Machine Learning Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Machine Learning Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Machine Learning Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Reinforcement Learning Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Reinforcement Learning Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Reinforcement Learning Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Supervised Learning Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Supervised Learning Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Supervised Learning Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Unsupervised Learning Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Unsupervised Learning Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Unsupervised Learning Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Nlp Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Nlp Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Nlp Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Language Translation Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Language Translation Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Language Translation Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Sentiment Analysis Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Sentiment Analysis Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Sentiment Analysis Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Text Mining Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Text Mining Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Text Mining Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Robotics Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Robotics Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Robotics Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global AI Pharma Market Size, by Product, 2017-2032 (USD Million)
TABLE 66. Global Hardware Solutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Hardware Solutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Hardware Solutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Clinical Trial Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Clinical Trial Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Clinical Trial Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Drug Discovery Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Drug Discovery Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Drug Discovery Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Patient Support Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Patient Support Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Patient Support Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Software Solutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Software Solutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Software Solutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Analytics Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Analytics Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Analytics Software Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Platform Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Platform Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Platform Software Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global AI Pharma Market Size, by Business Model, 2017-2032 (USD Million)
TABLE 91. Global Consulting Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Consulting Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Consulting Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Advisory Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Advisory Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Advisory Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Implementation Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Implementation Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Implementation Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Licensing Model Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Licensing Model Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Licensing Model Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Perpetual License Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Perpetual License Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Perpetual License Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Term License Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Term License Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Term License Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Platform Model Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Platform Model Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Platform Model Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Software As A Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Global Software As A Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. Global Software As A Service Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. Global Pay Per Use Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Global Pay Per Use Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. Global Pay Per Use Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. Global Subscription Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Global Subscription Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. Global Subscription Market Size, by Country, 2017-2032 (USD Million)
TABLE 121. Global AI Pharma Market Size, by Application, 2017-2032 (USD Million)
TABLE 122. Global Clinical Trials Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Global Clinical Trials Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. Global Clinical Trials Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. Global Phase I Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global Phase I Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global Phase I Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global Phase II Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Global Phase II Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. Global Phase II Market Size, by Country, 2017-2032 (USD Million)
TABLE 131. Global Phase III Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Global Phase III Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. Global Phase III Market Size, by Country, 2017-2032 (USD Million)
TABLE 134. Global Phase IV Market Size, by Region, 2017-2032 (USD Million)
TABLE 135. Global Phase IV Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. Global Phase IV Market Size, by Country, 2017-2032 (USD Million)
TABLE 137. Global Diagnostic Tools Market Size, by Region, 2017-2032 (USD Million)
TABLE 138. Global Diagnostic Tools Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. Global Diagnostic Tools Market Size, by Country, 2017-2032 (USD Million)
TABLE 140. Global Biomarker Analysis Market Size, by Region, 2017-2032 (USD Million)
TABLE 141. Global Biomarker Analysis Market Size, by Group, 2017-2032 (USD Million)
TABLE 142. Global Biomarker Analysis Market Size, by Country, 2017-2032 (USD Million)
TABLE 143. Global Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 144. Global Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. Global Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 146. Global Drug Discovery Market Size, by Region, 2017-2032 (USD Million)
TABLE 147. Global Drug Discovery Market Size, by Group, 2017-2032 (USD Million)
TABLE 148. Global Drug Discovery Market Size, by Country, 2017-2032 (USD Million)
TABLE 149. Global Compound Screening Market Size, by Region, 2017-2032 (USD Million)
TABLE 150. Global Compound Screening Market Size, by Group, 2017-2032 (USD Million)
TABLE 151. Global Compound Screening Market Size, by Country, 2017-2032 (USD Million)
TABLE 152. Global Preclinical Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 153. Global Preclinical Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 154. Global Preclinical Testing Market Size, by Country, 2017-2032 (USD Million)
TABLE 155. Global Target Identification Market Size, by Region, 2017-2032 (USD Million)
TABLE 156. Global Target Identification Market Size, by Group, 2017-2032 (USD Million)
TABLE 157. Global Target Identification Market Size, by Country, 2017-2032 (USD Million)
TABLE 158. Global Patient Monitoring Market Size, by Region, 2017-2032 (USD Million)
TABLE 159. Global Patient Monitoring Market Size, by Group, 2017-2032 (USD Million)
TABLE 160. Global Patient Monitoring Market Size, by Country, 2017-2032 (USD Million)
TABLE 161. Global Remote Monitoring Market Size, by Region, 2017-2032 (USD Million)
TABLE 162. Global Remote Monitoring Market Size, by Group, 2017-2032 (USD Million)
TABLE 163. Global Remote Monitoring Market Size, by Country, 2017-2032 (USD Million)
TABLE 164. Global Wearable Devices Market Size, by Region, 2017-2032 (USD Million)
TABLE 165. Global Wearable Devices Market Size, by Group, 2017-2032 (USD Million)
TABLE 166. Global Wearable Devices Market Size, by Country, 2017-2032 (USD Million)
TABLE 167. Global Supply Chain Management Market Size, by Region, 2017-2032 (USD Million)
TABLE 168. Global Supply Chain Management Market Size, by Group, 2017-2032 (USD Million)
TABLE 169. Global Supply Chain Management Market Size, by Country, 2017-2032 (USD Million)
TABLE 170. Global Cold Chain Logistics Market Size, by Region, 2017-2032 (USD Million)
TABLE 171. Global Cold Chain Logistics Market Size, by Group, 2017-2032 (USD Million)
TABLE 172. Global Cold Chain Logistics Market Size, by Country, 2017-2032 (USD Million)
TABLE 173. Global Inventory Management Market Size, by Region, 2017-2032 (USD Million)
TABLE 174. Global Inventory Management Market Size, by Group, 2017-2032 (USD Million)
TABLE 175. Global Inventory Management Market Size, by Country, 2017-2032 (USD Million)
TABLE 176. Global AI Pharma Market Size, by End User, 2017-2032 (USD Million)
TABLE 177. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 178. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 179. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 180. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 181. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 182. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 183. Global Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 184. Global Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 185. Global Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 186. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 187. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 188. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 189. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 190. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 191. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 192. Global AI Pharma Market Size, by Region, 2017-2032 (USD Million)
TABLE 193. Asia-Pacific AI Pharma Market Size, by Region, 2017-2032 (USD Million)
TABLE 194. Asia-Pacific AI Pharma Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 195. Asia-Pacific AI Pharma Market Size, by Technology, 2017-2032 (USD Million)
TABLE 196. Asia-Pacific AI Pharma Market Size, by Computer Vision, 2017-2032 (USD Million)
TABLE 197. Asia-Pacific AI Pharma Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 198. Asia-Pacific AI Pharma Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 199. Asia-Pacific AI Pharma Market Size, by Nlp, 2017-2032 (USD Million)
TABLE 200. Asia-Pacific AI Pharma Market Size, by Product, 2017-2032 (USD Million)
TABLE 201. Asia-Pacific AI Pharma Market Size, by Services, 2017-2032 (USD Million)
TABLE 202. Asia-Pacific AI Pharma Market Size, by Software Solutions, 2017-2032 (USD Million)
TABLE 203. Asia-Pacific AI Pharma Market Size, by Business Model, 2017-2032 (USD Million)
TABLE 204. Asia-Pacific AI Pharma Market Size, by Consulting Services, 2017-2032 (USD Million)
TABLE 205. Asia-Pacific AI Pharma Market Size, by Licensing Model, 2017-2032 (USD Million)
TABLE 206. Asia-Pacific AI Pharma Market Size, by Software As A Service, 2017-2032 (USD Million)
TABLE 207. Asia-Pacific AI Pharma Market Size, by Application, 2017-2032 (USD Million)
TABLE 208. Asia-Pacific AI Pharma Market Size, by Clinical Trials, 2017-2032 (USD Million)
TABLE 209. Asia-Pacific AI Pharma Market Size, by Diagnostic Tools, 2017-2032 (USD Million)
TABLE 210. Asia-Pacific AI Pharma Market Size, by Drug Discovery, 2017-2032 (USD Million)
TABLE 211. Asia-Pacific AI Pharma Market Size, by Patient Monitoring, 2017-2032 (USD Million)
TABLE 212. Asia-Pacific AI Pharma Market Size, by Supply Chain Management, 2017-2032 (USD Million)
TABLE 213. Asia-Pacific AI Pharma Market Size, by End User, 2017-2032 (USD Million)
TABLE 214. North America AI Pharma Market Size, by Region, 2017-2032 (USD Million)
TABLE 215. North America AI Pharma Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 216. North America AI Pharma Market Size, by Technology, 2017-2032 (USD Million)
TABLE 217. North America AI Pharma Market Size, by Computer Vision, 2017-2032 (USD Million)
TABLE 218. North America AI Pharma Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 219. North America AI Pharma Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 220. North America AI Pharma Market Size, by Nlp, 2017-2032 (USD Million)
TABLE 221. North America AI Pharma Market Size, by Product, 2017-2032 (USD Million)
TABLE 222. North America AI Pharma Market Size, by Services, 2017-2032 (USD Million)
TABLE 223. North America AI Pharma Market Size, by Software Solutions, 2017-2032 (USD Million)
TABLE 224. North America AI Pharma Market Size, by Business Model, 2017-2032 (USD Million)
TABLE 225. North America AI Pharma Market Size, by Consulting Services, 2017-2032 (USD Million)
TABLE 226. North America AI Pharma Market Size, by Licensing Model, 2017-2032 (USD Million)
TABLE 227. North America AI Pharma Market Size, by Software As A Service, 2017-2032 (USD Million)
TABLE 228. North America AI Pharma Market Size, by Application, 2017-2032 (USD Million)
TABLE 229. North America AI Pharma Market Size, by Clinical Trials, 2017-2032 (USD Million)
TABLE 230. North America AI Pharma Market Size, by Diagnostic Tools, 2017-2032 (USD Million)
TABLE 231. North America AI Pharma Market Size, by Drug Discovery, 2017-2032 (USD Million)
TABLE 232. North America AI Pharma Market Size, by Patient Monitoring, 2017-2032 (USD Million)
TABLE 233. North America AI Pharma Market Size, by Supply Chain Management, 2017-2032 (USD Million)
TABLE 234. North America AI Pharma Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. Latin America AI Pharma Market Size, by Region, 2017-2032 (USD Million)
TABLE 236. Latin America AI Pharma Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 237. Latin America AI Pharma Market Size, by Technology, 2017-2032 (USD Million)
TABLE 238. Latin America AI Pharma Market Size, by Computer Vision, 2017-2032 (USD Million)
TABLE 239. Latin America AI Pharma Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 240. Latin America AI Pharma Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 241. Latin America AI Pharma Market Size, by Nlp, 2017-2032 (USD Million)
TABLE 242. Latin America AI Pharma Market Size, by Product, 2017-2032 (USD Million)
TABLE 243. Latin America AI Pharma Market Size, by Services, 2017-2032 (USD Million)
TABLE 244. Latin America AI Pharma Market Size, by Software Solutions, 2017-2032 (USD Million)
TABLE 245. Latin America AI Pharma Market Size, by Business Model, 2017-2032 (USD Million)
TABLE 246. Latin America AI Pharma Market Size, by Consulting Services, 2017-2032 (USD Million)
TABLE 247. Latin America AI Pharma Market Size, by Licensing Model, 2017-2032 (USD Million)
TABLE 248. Latin America AI Pharma Market Size, by Software As A Service, 2017-2032 (USD Million)
TABLE 249. Latin America AI Pharma Market Size, by Application, 2017-2032 (USD Million)
TABLE 250. Latin America AI Pharma Market Size, by Clinical Trials, 2017-2032 (USD Million)
TABLE 251. Latin America AI Pharma Market Size, by Diagnostic Tools, 2017-2032 (USD Million)
TABLE 252. Latin America AI Pharma Market Size, by Drug Discovery, 2017-2032 (USD Million)
TABLE 253. Latin America AI Pharma Market Size, by Patient Monitoring, 2017-2032 (USD Million)
TABLE 254. Latin America AI Pharma Market Size, by Supply Chain Management, 2017-2032 (USD Million)
TABLE 255. Latin America AI Pharma Market Size, by End User, 2017-2032 (USD Million)
TABLE 256. Europe AI Pharma Market Size, by Region, 2017-2032 (USD Million)
TABLE 257. Europe AI Pharma Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 258. Europe AI Pharma Market Size, by Technology, 2017-2032 (USD Million)
TABLE 259. Europe AI Pharma Market Size, by Computer Vision, 2017-2032 (USD Million)
TABLE 260. Europe AI Pharma Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 261. Europe AI Pharma Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 262. Europe AI Pharma Market Size, by Nlp, 2017-2032 (USD Million)
TABLE 263. Europe AI Pharma Market Size, by Product, 2017-2032 (USD Million)
TABLE 264. Europe AI Pharma Market Size, by Services, 2017-2032 (USD Million)
TABLE 265. Europe AI Pharma Market Size, by Software Solutions, 2017-2032 (USD Million)
TABLE 266. Europe AI Pharma Market Size, by Business Model, 2017-2032 (USD Million)
TABLE 267. Europe AI Pharma Market Size, by Consulting Services, 2017-2032 (USD Million)
TABLE 268. Europe AI Pharma Market Size, by Licensing Model, 2017-2032 (USD Million)
TABLE 269. Europe AI Pharma Market Size, by Software As A Service, 2017-2032 (USD Million)
TABLE 270. Europe AI Pharma Market Size, by Application, 2017-2032 (USD Million)
TABLE 271. Europe AI Pharma Market Size, by Clinical Trials, 2017-2032 (USD Million)
TABLE 272. Europe AI Pharma Market Size, by Diagnostic Tools, 2017-2032 (USD Million)
TABLE 273. Europe AI Pharma Market Size, by Drug Discovery, 2017-2032 (USD Million)
TABLE 274. Europe AI Pharma Market Size, by Patient Monitoring, 2017-2032 (USD Million)
TABLE 275. Europe AI Pharma Market Size, by Supply Chain Management, 2017-2032 (USD Million)
TABLE 276. Europe AI Pharma Market Size, by End User, 2017-2032 (USD Million)
TABLE 277. Middle East AI Pharma Market Size, by Region, 2017-2032 (USD Million)
TABLE 278. Middle East AI Pharma Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 279. Middle East AI Pharma Market Size, by Technology, 2017-2032 (USD Million)
TABLE 280. Middle East AI Pharma Market Size, by Computer Vision, 2017-2032 (USD Million)
TABLE 281. Middle East AI Pharma Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 282. Middle East AI Pharma Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 283. Middle East AI Pharma Market Size, by Nlp, 2017-2032 (USD Million)
TABLE 284. Middle East AI Pharma Market Size, by Product, 2017-2032 (USD Million)
TABLE 285. Middle East AI Pharma Market Size, by Services, 2017-2032 (USD Million)
TABLE 286. Middle East AI Pharma Market Size, by Software Solutions, 2017-2032 (USD Million)
TABLE 287. Middle East AI Pharma Market Size, by Business Model, 2017-2032 (USD Million)
TABLE 288. Middle East AI Pharma Market Size, by Consulting Services, 2017-2032 (USD Million)
TABLE 289. Middle East AI Pharma Market Size, by Licensing Model, 2017-2032 (USD Million)
TABLE 290. Middle East AI Pharma Market Size, by Software As A Service, 2017-2032 (USD Million)
TABLE 291. Middle East AI Pharma Market Size, by Application, 2017-2032 (USD Million)
TABLE 292. Middle East AI Pharma Market Size, by Clinical Trials, 2017-2032 (USD Million)
TABLE 293. Middle East AI Pharma Market Size, by Diagnostic Tools, 2017-2032 (USD Million)
TABLE 294. Middle East AI Pharma Market Size, by Drug Discovery, 2017-2032 (USD Million)
TABLE 295. Middle East AI Pharma Market Size, by Patient Monitoring, 2017-2032 (USD Million)
TABLE 296. Middle East AI Pharma Market Size, by Supply Chain Management, 2017-2032 (USD Million)
TABLE 297. Middle East AI Pharma Market Size, by End User, 2017-2032 (USD Million)
TABLE 298. Africa AI Pharma Market Size, by Region, 2017-2032 (USD Million)
TABLE 299. Africa AI Pharma Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 300. Africa AI Pharma Market Size, by Technology, 2017-2032 (USD Million)
TABLE 301. Africa AI Pharma Market Size, by Computer Vision, 2017-2032 (USD Million)
TABLE 302. Africa AI Pharma Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 303. Africa AI Pharma Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 304. Africa AI Pharma Market Size, by Nlp, 2017-2032 (USD Million)
TABLE 305. Africa AI Pharma Market Size, by Product, 2017-2032 (USD Million)
TABLE 306. Africa AI Pharma Market Size, by Services, 2017-2032 (USD Million)
TABLE 307. Africa AI Pharma Market Size, by Software Solutions, 2017-2032 (USD Million)
TABLE 308. Africa AI Pharma Market Size, by Business Model, 2017-2032 (USD Million)
TABLE 309. Africa AI Pharma Market Size, by Consulting Services, 2017-2032 (USD Million)
TABLE 310. Africa AI Pharma Market Size, by Licensing Model, 2017-2032 (USD Million)
TABLE 311. Africa AI Pharma Market Size, by Software As A Service, 2017-2032 (USD Million)
TABLE 312. Africa AI Pharma Market Size, by Application, 2017-2032 (USD Million)
TABLE 313. Africa AI Pharma Market Size, by Clinical Trials, 2017-2032 (USD Million)
TABLE 314. Africa AI Pharma Market Size, by Diagnostic Tools, 2017-2032 (USD Million)
TABLE 315. Africa AI Pharma Market Size, by Drug Discovery, 2017-2032 (USD Million)
TABLE 316. Africa AI Pharma Market Size, by Patient Monitoring, 2017-2032 (USD Million)
TABLE 317. Africa AI Pharma Market Size, by Supply Chain Management, 2017-2032 (USD Million)
TABLE 318. Africa AI Pharma Market Size, by End User, 2017-2032 (USD Million)
TABLE 319. Global AI Pharma Market Size, by Group, 2017-2032 (USD Million)
TABLE 320. ASEAN AI Pharma Market Size, by Group, 2017-2032 (USD Million)
TABLE 321. ASEAN AI Pharma Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 322. ASEAN AI Pharma Market Size, by Technology, 2017-2032 (USD Million)
TABLE 323. ASEAN AI Pharma Market Size, by Computer Vision, 2017-2032 (USD Million)
TABLE 324. ASEAN AI Pharma Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 325. ASEAN AI Pharma Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 326. ASEAN AI Pharma Market Size, by Nlp, 2017-2032 (USD Million)
TABLE 327. ASEAN AI Pharma Market Size, by Product, 2017-2032 (USD Million)
TABLE 328. ASEAN AI Pharma Market Size, by Services, 2017-2032 (USD Million)
TABLE 329. ASEAN AI Pharma Market Size, by Software Solutions, 2017-2032 (USD Million)
TABLE 330. ASEAN AI Pharma Market Size, by Business Model, 2017-2032 (USD Million)
TABLE 331. ASEAN AI Pharma Market Size, by Consulting Services, 2017-2032 (USD Million)
TABLE 332. ASEAN AI Pharma Market Size, by Licensing Model, 2017-2032 (USD Million)
TABLE 333. ASEAN AI Pharma Market Size, by Software As A Service, 2017-2032 (USD Million)
TABLE 334. ASEAN AI Pharma Market Size, by Application, 2017-2032 (USD Million)
TABLE 335. ASEAN AI Pharma Market Size, by Clinical Trials, 2017-2032 (USD Million)
TABLE 336. ASEAN AI Pharma Market Size, by Diagnostic Tools, 2017-2032 (USD Million)
TABLE 337. ASEAN AI Pharma Market Size, by Drug Discovery, 2017-2032 (USD Million)
TABLE 338. ASEAN AI Pharma Market Size, by Patient Monitoring, 2017-2032 (USD Million)
TABLE 339. ASEAN AI Pharma Market Size, by Supply Chain Management, 2017-2032 (USD Million)
TABLE 340. ASEAN AI Pharma Market Size, by End User, 2017-2032 (USD Million)
TABLE 341. GCC AI Pharma Market Size, by Group, 2017-2032 (USD Million)
TABLE 342. GCC AI Pharma Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 343. GCC AI Pharma Market Size, by Technology, 2017-2032 (USD Million)
TABLE 344. GCC AI Pharma Market Size, by Computer Vision, 2017-2032 (USD Million)
TABLE 345. GCC AI Pharma Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 346. GCC AI Pharma Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 347. GCC AI Pharma Market Size, by Nlp, 2017-2032 (USD Million)
TABLE 348. GCC AI Pharma Market Size, by Product, 2017-2032 (USD Million)
TABLE 349. GCC AI Pharma Market Size, by Services, 2017-2032 (USD Million)
TABLE 350. GCC AI Pharma Market Size, by Software Solutions, 2017-2032 (USD Million)
TABLE 351. GCC AI Pharma Market Size, by Business Model, 2017-2032 (USD Million)
TABLE 352. GCC AI Pharma Market Size, by Consulting Services, 2017-2032 (USD Million)
TABLE 353. GCC AI Pharma Market Size, by Licensing Model, 2017-2032 (USD Million)
TABLE 354. GCC AI Pharma Market Size, by Software As A Service, 2017-2032 (USD Million)
TABLE 355. GCC AI Pharma Market Size, by Application, 2017-2032 (USD Million)
TABLE 356. GCC AI Pharma Market Size, by Clinical Trials, 2017-2032 (USD Million)
TABLE 357. GCC AI Pharma Market Size, by Diagnostic Tools, 2017-2032 (USD Million)
TABLE 358. GCC AI Pharma Market Size, by Drug Discovery, 2017-2032 (USD Million)
TABLE 359. GCC AI Pharma Market Size, by Patient Monitoring, 2017-2032 (USD Million)
TABLE 360. GCC AI Pharma Market Size, by Supply Chain Management, 2017-2032 (USD Million)
TABLE 361. GCC AI Pharma Market Size, by End User, 2017-2032 (USD Million)
TABLE 362. European Union AI Pharma Market Size, by Group, 2017-2032 (USD Million)
TABLE 363. European Union AI Pharma Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 364. European Union AI Pharma Market Size, by Technology, 2017-2032 (USD Million)
TABLE 365. European Union AI Pharma Market Size, by Computer Vision, 2017-2032 (USD Million)
TABLE 366. European Union AI Pharma Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 367. European Union AI Pharma Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 368. European Union AI Pharma Market Size, by Nlp, 2017-2032 (USD Million)
TABLE 369. European Union AI Pharma Market Size, by Product, 2017-2032 (USD Million)
TABLE 370. European Union AI Pharma Market Size, by Services, 2017-2032 (USD Million)
TABLE 371. European Union AI Pharma Market Size, by Software Solutions, 2017-2032 (USD Million)
TABLE 372. European Union AI Pharma Market Size, by Business Model, 2017-2032 (USD Million)
TABLE 373. European Union AI Pharma Market Size, by Consulting Services, 2017-2032 (USD Million)
TABLE 374. European Union AI Pharma Market Size, by Licensing Model, 2017-2032 (USD Million)
TABLE 375. European Union AI Pharma Market Size, by Software As A Service, 2017-2032 (USD Million)
TABLE 376. European Union AI Pharma Market Size, by Application, 2017-2032 (USD Million)
TABLE 377. European Union AI Pharma Market Size, by Clinical Trials, 2017-2032 (USD Million)
TABLE 378. European Union AI Pharma Market Size, by Diagnostic Tools, 2017-2032 (USD Million)
TABLE 379. European Union AI Pharma Market Size, by Drug Discovery, 2017-2032 (USD Million)
TABLE 380. European Union AI Pharma Market Size, by Patient Monitoring, 2017-2032 (USD Million)
TABLE 381. European Union AI Pharma Market Size, by Supply Chain Management, 2017-2032 (USD Million)
TABLE 382. European Union AI Pharma Market Size, by End User, 2017-2032 (USD Million)
TABLE 383. BRICS AI Pharma Market Size, by Group, 2017-2032 (USD Million)
TABLE 384. BRICS AI Pharma Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 385. BRICS AI Pharma Market Size, by Technology, 2017-2032 (USD Million)
TABLE 386. BRICS AI Pharma Market Size, by Computer Vision, 2017-2032 (USD Million)
TABLE 387. BRICS AI Pharma Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 388. BRICS AI Pharma Mark

Companies Mentioned

  • A2A Pharmaceuticals, Inc.
  • AbCellera Biologics Inc.
  • Adagene, Inc.
  • AiCure, Inc.
  • Aiforia Technologies Inc.
  • Aizon Network Corporation
  • Alector, Inc.
  • Altis Labs plc
  • Arpeggio Biosciences, Inc.
  • Arzeda, Inc.
  • Atomwise, Inc.
  • BenevolentAI Limited
  • Berg LLC
  • ChemPass Kft
  • Cloud Pharmaceuticals, Inc.
  • Cradle Bio B.V.
  • Exscientia plc
  • Insilico Medicine, Inc.
  • Isomorphic Labs Limited
  • Owkin, Inc.
  • Recursion Pharmaceuticals, Inc.
  • SOM Innovation Biotech, S.A.
  • XtalPi Holdings Limited

Related Topics

Related Reports

Artificial Intelligence (AI) in Pharma and Biotech - Global Strategic Business Report - Product Image

Artificial Intelligence (AI) in Pharma and Biotech - Global Strategic Business Report

  • Report
  • 142 Pages
  • Global
From
AI Biocomputing Big Model Market - Global Forecast 2026-2032 - Product Image

AI Biocomputing Big Model Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Wearables in Pharma & Biotech Market by Product, Therapy, Application, End User - Global Forecasts to 2031 - Product Image

Wearables in Pharma & Biotech Market by Product, Therapy, Application, End User - Global Forecasts to 2031

  • Report
  • 401 Pages
  • Global
From
Pharma 4.0 Market Size, Share & Trends Analysis Report by Type, Technology, Application, End Use, Region, and Growth Forecasts, 2026-2033 - Product Image

Pharma 4.0 Market Size, Share & Trends Analysis Report by Type, Technology, Application, End Use, Region, and Growth Forecasts, 2026-2033

  • Report
  • 120 Pages
  • Global
From
Pharma Predictive Analytics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Pharma Predictive Analytics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.